Literature DB >> 27121233

Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study.

Stefan Buettner1, Ana Wilson1, Georgios Antonis Margonis1, Faiz Gani1, Cecilia G Ethun2, George A Poultsides3, Thuy Tran3, Kamran Idrees4, Chelsea A Isom4, Ryan C Fields5, Bradley Krasnick5, Sharon M Weber6, Ahmed Salem6, Robert C G Martin7, Charles R Scoggins7, Perry Shen8, Harveshp D Mogal8, Carl Schmidt9, Eliza Beal9, Ioannis Hatzaras10, Rivfka Shenoy10, Shishir K Maithel2, Timothy M Pawlik11.   

Abstract

INTRODUCTION: Extrahepatic biliary malignancies are often diagnosed at an advanced stage. We compared patients with unresectable perihilar cholangiocarcinoma (PHCC) and gallbladder cancer (GBC) who underwent a palliative procedure versus an aborted laparotomy.
METHODS: Seven hundred seventy-seven patients who underwent surgery for PHCC or GBC between 2000 and 2014 were identified. Uni- and multivariable analyses were performed to identify factors associated with outcome.
RESULTS: Utilization of preoperative imaging increased over time (CT use, 80.1 % pre-2009 vs. 90 % post-2009) (p < 0.001). The proportion of the patients undergoing curative-intent resection also increased (2000-2004, 67.0 % vs. 2005-2009, 74.5 % vs. 2010-2014, 78.8 %; p = 0.001). The planned surgery was aborted in 106 (13.7 %) patients and 94 (12.1 %) had a palliative procedure. A higher incidence of postoperative complications (19.2 vs. 3.8 %, p = 0.001) including deep surgical site infections (8.3 vs. 1.1 %), bleeding (4.8 vs. 0 %), bile leak (6.0 vs. 0 %) and longer length of stay (7 vs. 4.5 days) were observed among the patients who underwent a palliative surgical procedure versus an aborted non-therapeutic, non-palliative laparotomy (all p < 0.05). OS was comparable among the patients who underwent a palliative procedure (8.7 months) versus an aborted laparotomy (7.8 months) (p = 0.23).
CONCLUSION: Increased use of advanced imaging modalities was accompanied by increased curative-intent surgery. Compared with patients in whom surgery was aborted, patients who underwent surgical palliation demonstrated an increased incidence of postoperative morbidity with comparable survival.

Entities:  

Keywords:  Biliary; Extrahepatic; Malignancy; Palliation; Surgical

Mesh:

Year:  2016        PMID: 27121233      PMCID: PMC5450034          DOI: 10.1007/s11605-016-3155-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  27 in total

Review 1.  Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resection.

Authors:  Kurinchi Selvan Gurusamy; Jun Li; Jessica Vaughan; Dinesh Sharma; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Palliation for suspected unresectable hilar cholangiocarcinoma.

Authors:  S Connor; E Barron; D N Redhead; H Ireland; K K Madhavan; R W Parks; O J Garden
Journal:  Eur J Surg Oncol       Date:  2006-12-15       Impact factor: 4.424

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5.

Authors:  Côme Lepage; Riccardo Capocaccia; Monika Hackl; Valerie Lemmens; Esther Molina; Daniela Pierannunzio; Milena Sant; Annalisa Trama; Jean Faivre
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

5.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.

Authors:  J R Andersen; S M Sørensen; A Kruse; M Rokkjaer; P Matzen
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

6.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

7.  Analysis of prognostic factors after surgery for stage III and IV gallbladder cancer.

Authors:  H Wakabayashi; K Ishimura; N Hashimoto; T Otani; A Kondo; H Maeta
Journal:  Eur J Surg Oncol       Date:  2004-10       Impact factor: 4.424

Review 8.  Palliation of hepatic tumors.

Authors:  Steven C Cunningham; Michael A Choti; Emily C Bellavance; Timothy M Pawlik
Journal:  Surg Oncol       Date:  2007-11-01       Impact factor: 3.279

9.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Practical guidelines for the surgical treatment of gallbladder cancer.

Authors:  Seung Eun Lee; Kyung Sik Kim; Wan Bae Kim; In-Gyu Kim; Yang Won Nah; Dong Hee Ryu; Joon Seong Park; Myung Hee Yoon; Jai Young Cho; Tae Ho Hong; Dae Wook Hwang; Dong Wook Choi
Journal:  J Korean Med Sci       Date:  2014-10-08       Impact factor: 2.153

View more
  2 in total

1.  [Intrahepatic cholangiocarcinoma : Results after 84 resections].

Authors:  H P Neeff; P A Holzner; M Menzel; P Bronsert; A Klock; S A Lang; S Fichtner-Feigl; U T Hopt; F Makowiec
Journal:  Chirurg       Date:  2018-05       Impact factor: 0.955

2.  Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma.

Authors:  Bas Groot Koerkamp; Stefan Buettner; Jaynee J A Vugts; Marcia P Gaspersz; Eva Roos; Lotte C Franken; Pim B Olthof; Robert J S Coelen; Jeroen L A van Vugt; Tim A Labeur; Lieke Brouwer; Marc G H Besselink; Jan N M IJzermans; Sarwa Darwish Murad; Thomas M van Gulik; Jeroen de Jonge; Wojciech G Polak; Olivier R C Busch; Joris L Erdmann
Journal:  Ann Surg Oncol       Date:  2020-09-08       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.